

CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22) Vijayaraghava Road, T. Nagar, Chennai - 600 017 Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482 Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN B.Com., FCA, MBIM (Lond.), Ph.d.

S. NEELAKANTAN B.Com., FCA

R. THIRUMALMARUGAN M.Com., FCA

B. RAMAKRISHNAN B.Com., Grad. CWA, FCA

V. VIVEK ANAND B.Com., FCA CHINNASAMY GANESAN B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY B.Com., FCA

NYAPATHY SRILATHA M.Com., FCA, PGDFM

E.K. SRIVATSAN B.Com., FCA

INDEPENDENT AUDITOR'S REPORT

To

The Partners, Argus Salud Pharma LLP Chennai-17.

Report on the Financial Statements

We have audited the accompanying financial statements of Argus Salud Pharma LLP (the LLP), which comprises the Balance Sheet as at March 31, 2017, the Statement of Profit and Loss for the year then ended and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of these financial statements that gives true and fair view of the financial position and financial performance of the LLP in accordance with the Accounting Standards issued by the Institute of Chartered Accountants of India. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements.



An audit involves performing procedures to obtain audit evidence about the amounts and disclosure in the financial statements. These procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessment, the auditor considers internal control relevant to the LLP's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing opinion on the LLP's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for audit opinion.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements, give the information required by the Limited Liability Partnership Act, 2008 and Limited Liability Partnership Rules, 2009 (As Amended) in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the LLP as at March 31, 2016; and its net Profit for the year ended on that date

Report on Other Legal and Regulatory Requirements

We report that:

- 1. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- 2. In our opinion proper books of account as required by law have been kept by the LLP so far as it appears from our examination of those books.
- 3. The Balance Sheet and the Profit and Loss Account, dealt with by this Report are in agreement with the books of account.
- 4. In our opinion, the aforesaid financial statements comply with the Accounting Standards issued by ICAI.

Place: Chennai Date: 10-05-2017 For M/s CNGSN & Associates LLP Chartered Accountants
Firm Regn. No: 4915S/S200036

B. Ramakrishnan Partner

Membership No: 201023

		Salud Pharmo			
Balai	SCH No.	et as at 31st	As at 31-03-2017 Rs.		As at 31-03-2016 Rs.
SOURCES OF FUNDS					
SHARE HOLDERS' FUNDS Partners' Capital Account Caplin Point Laboratories Ltd May India Properties P Ltd		99,00,000	99,10,000	99,00,000	99,10,000
Partners' Share of Profit Caplin Point Laboratories Ltd May India Properties P Ltd	2	463,58,650, 27,21,881	490,80,531	786,78,605 26,93,701	813,72,305
TOTAL			589,90,531		912,82,305
APPLICATION OF FUNDS	-			A CONTRACTOR OF THE CONTRACTOR	
FIXED ASSETS Gross Block Less: Accumulated Depreciation Net Block	3	-	-	206,97,890 59,18,824	147,79,066
CURRENT ASSETS, LOANS & ADVANCES					
Inventories Sundry Debtors Cash & Bank balances Loans, Advances & Deposits	4 5 6 7		- 451,71,780 88,20,513 73,98,590 613,90,883		91,71,925 756,79,831 333,46,715 261,36,428 1443,34,899
CURRENT LIABILITIES & PROVISIONS					
Current Liabilities Provisions	8 9		18,38,356 5,61,996 24,00,352		647,16,858 31,14,802 678,31,660
NET CURRENT ASSETS			589,90,531		765,03,240
TOTAL			589,90,531		912,82,30

Notes Forming Part of the Accounts and Significant Accounting Policies

As per our report of even dated attached

for CNGSN & Associates LLP

Chartered Accountants

Firm Registration No: 4915S/ S200036

B.RAMAKRISHNAN

Partner

1CAI Membership No: 201023

Place: Chennai Date: May 10, 2017

For and on behalf ARGUS SALUD PHARMA LLP

CHENNAI

on behalf of May India Property Pvt Ltd Designated Partner

Caplin Point Laboratories Ltd Designated Partner

	us Salud Pharm		
Profit and Loss Acco	unt for the Year	ended 31st March 2017	
		For the Year ended 31-03-2017	For the Year ended 31-03-2016
	SCH		
	NO.	Rs.	Rs.
INCOME			0000 05 000
Gross Sales (Less Returns)		1711,57,864	2809,25,883
Less: Excise Duty		1711.57.064	2809.25,883
Net Sales		1711,57,864 49,91,709	41,07,327
Export Incentives		31,52,829	70,34,407
Other Income	10	31,32,629	707,707
TOTAL		1793,02,402	2920,67,617
EXP <u>ENSES</u>			
Cost of Goods Sold	11	1012,75,421	1834,52,190
Direct Expenses	12	14,01,228	50,43,576
Payments to and Provision for employees	13	13,07,271	41,57,138
Administrative Overheads	14	132,84,640	88,90,144
Interest and Finance Charges	15	1,15,928	4,95,866
Selling Overheads	16	15,54,543	18,36,318
TOTAL		1189,39,032	2038,75,232
PROFIT BEFORE DEPRECIATION AND TAX		603,63,370	881,92,385
Depreciation and Amortisation		3,55,422	20,38,494
PROFIT BEFORE TAX		600,07,948	861,53,891
Provision for Taxation - Current		(318,27,283)	(195,89,394)
- Earlier years		-	-
- Deferred Tax	1	-	-
Add: MAT credit entitlement		281,80,665	665,64,497
PROFIT AFTER TAX		281,00,003	003,04,427
		-	-
Balance carried to Partners'Capital a/c		281,80,665	665,64,497
Could Point I de contactor I		281,52,484	662,97,197
Caplin Point Laboratories L May India Properties P Lt		28,181	2,67,300
May india Properties P LA	u	281,80,665	665,64,497
	ļ		

Notes Forming Part of the Accounts and Significant Accounting Policies

As per our report of even dated attached for CNGSN & Associates

Chartered Accountants

Firm Registration No: 4915S/ S200036

B.RAMAKRISHNAN

Partner

ICAI Membership No: 201023

Place: Chennai Date: May 10, 2017

For and on behalf ARGUS SALUD PHARMA LLP

on behalf of May India Property Pvt Ltd Designated Partner

Caplin Point Laboratories Ltd Designated Partner

SCHEDULES FORMING PART OF THE ACCOUNTS

Schedules forming part of Accounts for the period ended 31st Mar 2017

SCHEDULE 1 -- PARTNERS' SHARE CAPITAL

Caplin Point Laboratories Ltd May India Properties P Ltd

	As at 31-03-2017 Rs.
99.00,000 10,000	99,10.000
	99,10,000

	As at 31-03-2016 Rs.
99.00.000 10,000	99.10,000
	99,10,000

			As at 31-03-2017 Rs.
SCHEDULE 2 PARTNER	S' SHARE of Profit		
Caplin Point Laboratories Ltd			
	Opening	786,75,941	
	For the year	281,52,484	
	· [1068,28,423	
	Less: Amount transferred from Partners Current Account	604,69,773	463,58,650
May India Properties P Ltd			
iviay maia i roperties : Dis	Opening	26,93,701	
	For the year	28,180	
		27,21,881	27,21,881
			490,80,531
	Į.		170,00,10

	As at 31-03-2016 Rs.
2391,82,891	
662,97,197	
3054,80,088	
2268,01,483	786,78,605
24,26,401	
2,67,300	
26,93,701	26,93,701
	813,72,305



SCHEDULES FORMING PART OF THE ACCOUNTS

Schedules forming part of Accounts for the period ended 31st Mar 2017

SCHEDULE 4 -- INVENTORIES

(As certified by the Management)
Raw Materials
Work-in-Progress
Finished Goods

SCHEDULE 5 -- SUNDRY DEBTORS

 (i) Debts outstanding for a period exceeding six months Unsecured and Considered Good Unsecured and Considered Doubtful

(ii) Other Debts
Unsecured and Considered Good
Unsecured and Considered Doubtful

SCHEDULE 6 -- CASH & BANK BALANCES

(i) Cash on Hand

(ii) Balance with scheduled banks in Current Accounts in Deposit Accounts

SCHEDULE 7 -- LOANS, ADVANCES & DEPOSITS

(Unsecured, considered good unless otherwise stated)

Advances Recoverable in each or in kind or for value to be received

Advances - Income tax
Deposits with Statutory / Govt. Authorities
Balance with Sales Tax Authorities
Advances - Others
Deposits

SCHEDULE 8 -- CURRENT LIABILITIES

Sundry Creditors - Goods

- Expenses

- Capital goods

Sundry Creditors - Others

SCHEDULE 9 -- PROVISIONS

Provision for Tax

As at 31-03-2017 Rs.		As at 31-03-2016 Rs.
-		30,50,386 35,80,099 25,41,440 91,71,925
 -		-
451,71,780		756,79,831
50,021		756,79,831 6,81,924
85,71,795 1,98,697		 44,36,991 282,27,800
88,20,513	-	333,46,715
		-
17,90,141 48,69,339 7,39,110 73,98,590		21,71,834 232,89,672 6,74,922 261,36,428
14,84,495 3,53,318 - 543		360,39,844 285,16,266 149 1,60,599
18,38,356		647,16,858
5,61,996 5,61,996	1.	31,14,802 31,14,802



SCHEDULES FORMING PART OF THE ACCOUNTS

SCHEBULES FORMING PART	OF THE ACCOU	INTS		
Schedules forming part of Accounts for the period ended 31st May 2017	For the Ye	ar ended 31-03-2017 Rs.	For the Year	ended 31-03-2016 Rs.
SCHEDULE 10 - INDIRECT INCOME				
Interest Income Exchange Fluctuation Income (nett) Miscellaneous income		20,96,333 8,59,471 1,97,025		25,62,751 44,71,656
NISCEIARCOUS INCOME		31,52,829		70,34,407
SCHEDULE 11 COST OF GOODS SOLD				
Opening Stock:	30,50,386		102,65,620	
Raw Materials Work-in-Progress	35,80,099		27,02,035 1,47,550	
Finished Goods	25,41,440	91,71,925	137,330	131,15,204
Add: Purchases:				Ì
Raw Materials (Less Returns)	921,03,496		622,92,390	
Finished Goods	72.1,03,470	921,03,496		1795,08,911
Less: Closing Stock:			30,50,386	
Raw Materials Work-in-Progress	-		35,80,099 25,41,440	
Finished Goods	-	-	25,41,410	91,71,926
		1012,75,421		1834,52,190
SCHEDULE 12 DIRECT EXPENSES]			20.22.205
Manufacturing Expenses		8,58,597 5,42,631		29,27,395 21,16,181
Power and Fuel		14,01,228		50,43,576
Schedules forming part of Accounts for the period	For the	Year ended 31-03-2017	For the Yo	31-03-2016
ended 31st Mar 2017		Rs.		Rs.
SCHEDULE 13PAYMENTS TO AND PROVISION FOR EMPLOYEES			1	
		6,14,227		31,75,285
Salaries, Wages & Bonus Contribution to Provident Fund and other funds		55,538		3,35,706 6,46,147
Staff Welfare		6,37,506		
		13,07,271		41,57,138
SCHEDULE 14 ADMINISTRATIVE OVERHEADS Telephone Expenses		72,318		2,90,907
Donations		5,200 3,03,781		13,201 2,31,617
Professional and Consultancy Rates & Taxes		74,931		99,114
Bad debts Subscriptions		38,50,168 20,988		24,496
Travelling & Conveyance		6,22,537 80,000	1	8,05,920 80,000
Audit fees Insurance		1,38,619		1,99,671
Repairs and Maintenance		-		2,29,807
- Building - Others		4,37,370 11,57,810		26,79,059 28,88,508
Rent & Amenities Loss on sale of assets		43,44,798		-
Sundry Expenses		21,76,120 132,84,640		13,47,844 88,90,144
	-			
SCHEDULE 15 INTEREST AND FINANCE CHARGES				1
Interest - on Term Loans		233		-
- Others Bank Charges		1,15,695		4,95,866
		1,15,928		4,95,866
SCHEDULE 16 - SELLING OVERHEADS Sales Promotion expense		-		12
A decading mont		3,200 4,20,526		2,41,488 8,40,918
Freight outwards Other Selling Expenses		11,30,817		7,53,900 18,36,31
/S/ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		15,54,543		18,36,313



ARGUS SALUD PHARMA LLP SCHEDULE 14

SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2017

A. SIGNIFICANT ACCOUNTING POLICIES

1. Basis of preparation of financial statements

The accounts are prepared on historical costs convention and in accordance with the accounting principles generally accepted in India comprising the accounting standards issued by the Institute of Chartered Accountants of India and the provisions of the Companies Act, 1956. The Financial Statements are drawn up on accrual basis.

2. Recognition of Income and Expenditure

The firm adopts mercantile system of accounting and recognizes income and expenditure on accrual basis in accordance with the applicable accounting standards

3. Revenue Recognition

Sale of goods is recognized when the risk and rewards of ownership are passed on to the customers, which is generally on dispatch of goods. Gross sales include excise duty but exclude value added tax/sales tax. Export sales are accounted for on the basis of date of bill of lading.

4. Fixed Assets

Fixed assets are valued at original cost of acquisition less depreciation. The actual cost capitalized includes freight, installation cost, duties and taxes, and other incidental expenses attributable to bringing the asset to its working condition.

5. Depreciation

- a. Depreciation on Fixed Assets is calculated on Straight Line method at rates prescribed in Schedule XIV of the Companies Act, 1956, on original cost of the asset. Additions to fixed assets costing less than Rs. 5000/- are fully charged off as depreciation in the year of addition.
- b. The cost and accumulated depreciation for fixed assets sold, retired or otherwise disposed off are removed from the stated values and the resulting gains and losses are included in the Profit and Loss account.
- c. Depreciation has been calculated, on additions, in pro-rata to the number of months for which they have been in existence.

6. Foreign Currency Transactions

- a. Foreign currency transactions are translated at exchange rates prevailing on the date of transactions.
- b. Foreign currency monetary assets and liabilities are reported at the closing rate. Gain and losses arising on account of difference in foreign exchange rates on settlement/translation of Monetary Assets and Liabilities on the closing date are recognized in the Profit and Loss Account.

7. Inventories

- a. Raw material, Packing materials, stores and spares are valued at cost including duties and taxes, exclusive of MODVAT credit. The cost is arrived at FIFO basis.
- b. The finished goods inventories are valued on the principles of cost or net realizable value whichever is lower. The cost includes the cost of raw materials, packing materials and other related expenses.
- c. Work in progress is valued on the same basis as finished goods and is inclusive of their cost of raw materials, packing materials and other related expenses.
- d. Value of closing stock as on 31st March 2017 is as certified by the management.

8. Retirement benefits

a. Defined Contribution Plans

Contributions paid/payable under defined contribution plans are recognized in the Profit and Loss Account each year. Contribution plan is for Provident Fund administered and managed by the Government of India. The Company makes monthly contributions and has no further obligations under the plan beyond its contributions

b. Short-term employment benefits

The undiscounted amount of short term employee benefits expected to be paid in exchange for the services rendered by employees is recognized during the period when the employee renders the service. These benefits include compensated absences such as paid annual leaves and performance incentives.

9.Leases

Lease of assets where the less or effectively retains all the risks and rewards of ownership are classified as operating leases. Lease payments under operating leases are recognized as expenses on accrual basis in accordance with the respective lease agreements.

- 10. Contingent liabilities are not provided for, but disclosed in the Notes on Accounts
- 11. The Company is operating in one segment of "pharmaceutical formulations".



1.

B. NOTES ON ACCOUNTS

1. Contingent Liabilities

(a) Outstanding Bank Guarantee given to the Customs department and others Rs. 1,47,800/- (Previous Year Rs. 1,47,800/-)

2. Dues to Micro, Small and Medium Enterprises

The Firm has not received information from Vendors regarding their status under the Micro, Small and Medium Enterprises Development Act 2006 and hence disclosure relating to amount unpaid as at the year end together with Interest Paid / Payable under this Act have not been given.

3. Balances with Scheduled banks in deposit accounts includes:

- (a) Deposits under lien towards Bank Guarantee Rs. 7,49,089/- (Rs. 7,49,089/-)
- 4. Balances of debtors, loans, advances and deposits, including items which are subject to confirmation, have, in the opinion of the management, a value on realization in the ordinary course of business at least equal to the amount at which they are stated and creditors are stated at the value which they are liable to be paid.

5. Auditors' Remuneration comprises of fees:

	In Rs. For the Year ended March 31, 2017	In Rs. For the Year ended March 31, 2016
For Statutory Audit	70000	70000
For Tax Audit	10000	10000
Total	80000	80000
6. CIF Value of Imports		
	In Rs.	In Rs.
	For the year ended	For the year ended
	March 31, 2017	March 31, 2016
Raw materials ,Finished Goods	29231901/-	80215383 /-

7. Earnings in Foreign Exchange (On Accrual basis)

FOB Value of Exports -

Capital Goods

15,97,04,440 Rs. /- (Previous Year Rs. 188771526 /-)



8. Value of consumption of imported and indigenous materials and components

	For the year ended M 2017		For the year ended N 2016	March 31,
	Rs.	%	Rs.	%
Imported	NIL/-		184800/-	0.30%
Indigenous	NIL/-		62107590/-	99.70%
	NIL		62292390/-	100%

9. Licensed and Installed Capacity and actual production

Qty in units in lakhs

	Annual Licensed / Installed Capacity	Actual Production	Annual Licensed / Installed Capacity	Actual Production
	2016-17	2016-17	2015-16	2015-16
Tablets	-	-	72.00	**
Capsules		-	1320.00	175.95
Ointments/Cream	-	-	156.00	14.83
Liquids	~	-	N/A	Pr-

10. Details regarding purchase of Traded Goods

	2016-	17	2015-	16
Category	Qty	Value	Qty	Value
	Nos in Lakhs	Rs. In Lakhs	Nos in Lakhs	Rs. In Lakhs
Tablets	315.94	524.43	105.62	65.75
Capsules	.59	85.116	36.23	117.66
Liquids	2.39	12.456	4.11	65.56
Injection	2.23	88.998	1.66	27.89
Ointments	1.80	36.888	-	1.18
Softgels	19.46	24.24	_	-
Syrup	6.10	143.048	•	-
Others	.12	6.03	6.51	37.46
Total	354.19	921.206	154.17	315.51



11. Sale of Product comprises

Category	Manufactured Goods				Traded Goods				
	2016-17		2015-16		2016-17		2015-16		
	Qty	Value	Qty	Value	Qty	Value	Qty	Value	
Tablets			-	-	315.94	924.05	105.62	123.31	
Capsules		-	175.95	103.38	.59	141.86	36.23	177.54	
Liquids	-	-	-	_	2.39	20.76	4.11	120.12	
Injectables		+	-	-	2.23	148.33	1.66	36.26	
Ointments	-	-	14.83	170.21	1.80	61.48	-	-	
Softgels	-	-	-	-	19.46	40.40	-	-	
Syrup					6.10	250.08			
Others	_	-	_	-	.12	10.05	6.51	48.49	
Total		-	190.78	273.60	354.19	1597.04	154.17	508.69	

12. Details of Closing Stock at

	MANUFACTURED GOODS				Traded Goods			
ľ	2016-17		2015-16		2016-17		2015-16	
CATEGORY	Qty	Value	Qty	Value	Qty	Value	Qty	Value
Tablets	-	-	-	-	-	-	25.53	8.31
Capsules	_	_	1.72	0.86	-	-	5.76	14.40
Ointments	-	-	0.31	1.71	-	· -	-	*
Liquids	-	-	_	-	_	-	-	-
OTHERS	_	-	0.003	0.13	-	**	-	
Total	-	-	2.06	2.70	•	-	31.29	22.71

13. Operating Leases

The company has entered into cancelable lease agreements for office facilities, office and residential premises of employees. Lease payments recognized in the Profit & Loss Account for the year Rs. 11,57,810/- The Company has not entered into any non cancelable operating leases and finance leases.

- 14. Disclosure in accordance with the Accounting Standard 18 "Related Party Disclosures" issued by the Institute of Chartered Accountants of India as identified by the company and relied upon by the auditors.
 - (a) Related parties and nature of relationship
 - Caplin Point Laboratories Ltd



- (b) Key management personnel
 - Mr. Manish Production Executive
- (c) Transactions that have taken place during the year with related parties by the company:

	III IX.5.		
	For the year ended 31st March 2017	For the year ended 31st March 2016	
Sales to related party	4,90,33,818/-	92089577/-	
Purchase from Related party	1,11,21,179/-	26625170/-	
Share of profit of related party	2,81,13,845/-	66299990/-	

- 15. The firm's factory unit at Baddi in Himachal Pradesh is having exemption from Income Tax for a period of 10 years from the date of commencement of production (Year 2010 2011).
- 16. The firm operates in one segment only viz., pharmaceutical formulations.
- 17. Previous year's figures have been regrouped wherever necessary.

CHENNAI

Signatories to Schedules 1 to 17

As per our report of even dated attached

for CNGSN & Associates

Chartered Accountants

Firm Registration No. 004915S/S200036

For and on behalf of ARGUS SALUD PHARMA LLP

B.RAMAKRISHNAN

1. samat

Partner

ICAI membership No 201023

Date:10.05.2017 Place:Chennai on behalf of

May India Property Private Ltd

Designated Partner

on behalf of Caplin Point Laboratories Ltd

Designated Partner